Poster Spotlight Session 8: Antibody Drug Conjugates: Where are We Headed?
Wednesday, December 6 • 5:30 pm – 6:30 pm • Hemisfair Ballroom 1-2
Presentation: Efficacy of Sacituzumab-Govitecan (SG) post Trastuzumab-deruxtecan (T-DXd) and vice versa for HER2low advanced or metastatic breast cancer (MBC): a French multicentre retrospective study
Francois Poumeaud, MD
Oncopole Claudius Régaud IUCT-O,
Toulouse, France
What is your presentation about?
My presentation will focus on the efficacy of subsequent use of two antibody drug conjugates (ADC) when used one after another: Sacituzumab-Govitecan (SG) and Trastuzumab-Deruxtecan (T-DXd). These ADCs have brought a clinically significant advantage for both hormone receptor positive (HR+) and negative (HR-) / HER2-low metastatic breast cancer (MBC). However, they share a payload from the same therapeutic class (Topoisomerase 1 inhibitor) exposing them to acquired payload cross-resistance. We provide data from the largest real-world cohort to date exploring the efficacy of the second ADC (ADC2) in this setting.
What makes this topic important in 2023?
Updated European guidelines have recently recommended the subsequent use of these two ADCs in patients with HER2-low MBC and new ADCs (such as Datopotamab-Deruxtecan) might be available as well for these patients. Our results emphasize the need to identify the subgroup of patients who might benefit from several ADCs from those who might be primary progressive after being exposed to a first ADC (ADC1) and the urgent need to develop therapeutic sequences trials. In the era of personalized medicine, we may all take advantage of these first real-world data.
How did you get involved in this particular area of breast cancer research, care, or advocacy?
As a young medical oncologist, I had the opportunity to live the advent of this new therapeutic class (ADC) in breast cancers, especially in patients with poor prognosis such as patients with TNBC. However, I was concerned to know which patient would really benefit from a therapeutic escalation with ADC, from those who might not. With the experience and permanent support of my mentor, Pr Dalenc, I had the chance to run this national study, with the goal of improving patients’ outcomes.
Presentation: Impact of HER2 expression dynamics on the real-world activity of trastuzumab deruxtecan for metastatic breast cancer (RELIEVE)
Paolo Tarantino, MD
Dana-Farber Cancer Institute, Harvard Medical School,
Boston, Massachusetts
What is your presentation about?
We reviewed the activity of the novel antibody-drug conjugate T-DXd among patients with different levels and different dynamics of HER2 expression. In addition, we have conducted translational analyses to develop biomarkers that may predict the benefit of T-DXd upfront.
What makes this topic important in 2023?
The use of antibody-drug conjugates is rapidly expanding in oncology, with T-DXd in particular that is currently used for HER2+ and HER2-low breast cancer but is expected to soon receive an agnostic indication. Producing real-world data with this agent is extremely important, and even more important is to develop biomarkers able to understand which patients are more likely to respond, and which instead may benefit more from different therapeutic strategies.